Recurrent Erlotinib-Induced Interstitial Lung Disease on Non-Small Cell Lung Cancer
°áÇÙ¹×È£Èí±âÁúȯ 2009³â 67±Ç 5È£ p.445 ~ p.448
¹Ú»óµ·(Park Sang-Don) - ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è¾Æ¸§(Kim A-Reum) - ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹ÚÁø¼®(Park Jin-Seok) - ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
½Åõȣ(Shin Chun-Ho) - ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
³²Çؼº(Nam Hae-Sung) - ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è·ç½Ã¾Æ(Kim Lucia) - ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
Á¶ÀçÈ(Cho Jae-Hwa) - ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
·ùÁ¤¼±(Ryu Jeong-Seon) - ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
°û½Â¹Î(Kwak Seung-Min) - ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Erlotinib (Tarceva¨Þ) has been considered to be a new, promising oral chemotherapy agent for local advanced or metastatic non-small cell lung cancer (NSCLC). Erlotinib is regarded as relatively safe, but interstitial lung disease
(ILD) related to erlotinib has been reported on an infrequent basis in Asia. We report an histologically confirmed case of recurrent erlotinib-induced ILD. Although, the patient was highly responsive to the first erlotinib treatment, the therapy was discontinued due to erlotinib-induced ILD. After intravenous high dose methylpredinisolone treatment, ILD was improved rapidly by radiologic studies, but the particular lung cancer re-emerged. We restarted the patient erlotinib on low-dose oral methylpredinisolone, resulting in a recurrence of erlotinib-induced ILD. Our case suggests that re-administration of erlotinib should be performed on a limited basis in patients that have developed ILD on previous use, even if a therapeutic effect can be estimated.
Å°¿öµå
Erlotinib, Lung Diseases, Interstitial, Carcinoma, Non-Small-Cell Lung
KMID :
0383820090670050445
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
resulting in a recurrence of erlotinib-induced interstitial lung disease (ILD).